zoliflodacin zoliflodacin zoliflodacin (development codes azd0914 and etx0914) is an experimental antibiotic that is being studied for the treatment of infection with neisseria gonorrhoeae (gonorrhea). it has a novel mechanism of action which involves inhibition of bacterial type ii topoisomerases. it is being developed by entasis therapeutics and is (as of 2020) in phase iii clinical trials. zoliflodacinclinical dataother namesazd0914; etx0914pregnancycategory not classified yet routes ofadministrationoraldrug classantibioticlegal statuslegal status us: investigational new drug investigational pharmacokinetic databioavailability97.8%metabolismhepaticonset of actionfasted: 1.5–2.3 hfed: 4 helimination half-life5.3–6.3 hexcretionfaeces (79.6%)urine (18.2%)identifierscas number1620458-09-4pubchem cid76685216drugbank12817uniifwl2263r77keggd11726chemical and physical dataformulac22h22fn5o7molar mass487.444 g·mol−13d model (jsmol)interactive image smiles c1cn2((o1)c)c3(cc4=c2c(=c5c(=c4)c(=no5)n6(coc6=o)c)f)c(=o)nc(=o)nc3=o inchi inchi=1s/c22h22fn5o7/c1-8-7-33-21(32)28(8)17-12-4-11-5-22(18(29)24-20(31)25-19(22)30)16-10(3)34-9(2)6-27(16)14(11)13(23)15(12)35-26-17/h4,8-10,16h,5-7h2,1-3h3,(h2,24,25,29,30,31)/t8-,9+,10-,16+/m0/s1key:zswmifnwdqexdt-zesjgqacsa-n